Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).

Alyssa A TooropZoë Ygj van LieropLiza My GelissenElske HoitsmaEsther Mpe ZeinstraLuuk C van RooijCaspar Ep van MunsterAnke VennegoorJop P MostertBeatrijs Ha WokkeNynke F KalkersErwin Lj HoogervorstJeroen Jj van EijkChristiaan M RoosendaalJolijn J KragtMarijke EurelingsJessie van GenugtenJessica NielsenLgf SinnigeMark E KloosterzielEdo Pj ArnoldusGert W van DijkWillem H BouvyMark Hj WesselsLynn BoonkampEva M M StrijbisBob W van OostenBrigit A De JongBirgit I Lissenberg-WitteFrederik BarkhofBastiaan MoraalCharlotte E TeunissenTheo RispensBernard Mj UitdehaagJoep KillesteinZoé Léonie Elise van Kempen

Published in: Journal of neurology, neurosurgery, and psychiatry (2023)

NCT04225312.

Keyphrases

multiple sclerosis
phase iii
study protocol
phase ii
white matter
clinical trial
open label
randomized controlled trial
mass spectrometry
rheumatoid arthritis